<DOC>
	<DOCNO>NCT01478022</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics plasma profile 3 treatment : ISO 20 , IBU 200 IBU ISO combination ( 200 +20 ) give single dose . This study conduct support submission new indication treatment combination Isosorbide Dinitrate Ibuprofen treatment Duchenne muscular dystrophy .</brief_summary>
	<brief_title>To Compare Pharmacokinetics Profiles ISO 20 , IBU 200 IBU Plus ISO Combinations 200 + 20</brief_title>
	<detailed_description>This trial design define drug interaction follow combined administration Isosorbide Dinitrate , NO donor , ibuprofen , NSAID , pharmacokinetics approach . Both ibuprofen Isosorbide Dinitrate license worldwide . Ibuprofen approve use adult child ; Isosorbide approve use adult . Ibuprofen currently use pediatric patient first line anti-inflammatory antipyretic agent . Consensus exist among NSAIDs ibuprofen one endow less adverse effect ( see note 66 Italian Drug Agency AIFA MEA ) . No specific study concern safety tolerability ISDN pediatric patient report .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy freeliving Males age 18 27 Normal ECG Body Mass Index 19.029.0 ( Kg/m2 ) Subject healthy opinion Investigator Signed informed consent verbal write information Clinically significant underlying systemic illness may preclude subject 's ability complete trial Any Gastrointestinal condition , opinion Investigator , may interfere absorption drug render subject unable take oral medication ( gastric ulcer , peptic ulcer , stomach acid , frequent diarrhea , gastrointestinal surgery ) History follow cardiac disease SBP &lt; 120 mmHG DBP &lt; 80 mmHg Platelet count &lt; 100000/mm3 History recurrent headache History ongoing clinically relevant glaucoma History alcohol , drug medication abuse within past 2 year Treatment norepinephrine , acetylcholine histamine History presence allergy intolerance study drug component drug class , history drug allergy , opinion physician responsible , contraindicate participation Participation another study phase 1 investigational product within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>27 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>DMD</keyword>
	<keyword>Duchenne</keyword>
	<keyword>Muscular Dystrophy</keyword>
</DOC>